Post-traumatic stress disorder (PTSD) is a delayed and persistent mental disorder that occurs when an individual experiences, witnesses, or encounters one or more actual deaths involving himself or others, or is threatened with death, or is severely injured, or whose physical integrity is threatened.The incidence of PTSD has been reported inconsistently, with women more likely to develop PTSD than men.
Post-Traumatic Stress Disorder Market contains market size and forecasts of Post-Traumatic Stress Disorder (PTSD) in Global, including the following market information:
- Global Post-Traumatic Stress Disorder (PTSD) Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global top five companies in 2021 (%)
The global Post-Traumatic Stress Disorder (PTSD) market was valued at 2479.9 million in 2021 and is projected to reach US$ 3176.2 million by 2028, at a CAGR of 3.6% during the forecast period.
- The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
- Cognitive Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
- The global key manufacturers of Post-Traumatic Stress Disorder (PTSD) include GlaxoSmithKline (UK), Pfizer (US), Eli Lilly and Company (US), Lundbeck A/S (Denmark), Azevan Pharmaceuticals (US), Marinus Pharmaceuticals, Inc. (US), Tonix Pharmaceuticals Holding Corp. (US), Bionomics (Australia) and Greenstone LLC (US), etc. In 2021, the global top five players have a share approximately % in terms of revenue.
- We surveyed the Post-Traumatic Stress Disorder (PTSD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Post-Traumatic Stress Disorder (PTSD) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Post-Traumatic Stress Disorder (PTSD) Market Segment Percentages, by Type, 2021 (%)
- Cognitive Therapy
- Exposure Therapy
- Eye Movement Desensitization And Reprocessing (EMDR)
- Antidepressants
- Anti-Anxiety Medications
- Prazosin
Global Post-Traumatic Stress Disorder (PTSD) Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Post-Traumatic Stress Disorder (PTSD) Market Segment Percentages, by Application, 2021 (%)
Global Post-Traumatic Stress Disorder (PTSD) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Post-Traumatic Stress Disorder (PTSD) Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Post-Traumatic Stress Disorder (PTSD) revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Post-Traumatic Stress Disorder (PTSD) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- GlaxoSmithKline (UK)
- Pfizer (US)
- Eli Lilly and Company (US)
- Lundbeck A/S (Denmark)
- Azevan Pharmaceuticals (US)
- Marinus Pharmaceuticals, Inc. (US)
- Tonix Pharmaceuticals Holding Corp. (US)
- Bionomics (Australia)
- Greenstone LLC (US)
- Mylan NV (US)
- Otsuka Pharmaceutical (Japan)
- Prometheon Pharma (USA)
- Ligand Pharma (USA)
- Valenta Pharm (Russia)
- Lycera Corp (US)
- Archimedes (UK)
- GMP Endotherapeutics (USA)
- Nuvo Pharmaceuticals (Canada)
- Beijing Wansheng Pharmaceutical
- Zhejiang Huahai Pharmaceutical
- Zhejiang Jianfeng Pharmaceutical
Industry Market Size
